Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
134.00
+2.50 (1.90%)
May 29, 2026, 1:30 PM CST
Market Cap12.32B -5.7%
Revenue (ttm)1.03B +8.6%
Net Income473.03M +9.1%
EPS4.56 -2.0%
Shares Out 91.98M
PE Ratio28.02
Forward PEn/a
Dividend3.33 (2.49%)
Ex-Dividend DateApr 16, 2026
Volume234,249
Open132.00
Previous Close131.50
Day's Range132.00 - 134.00
52-Week Range120.95 - 179.05
Beta0.41
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6712
Full Company Profile

Financial Performance

In 2025, TPEX:6712's revenue was 1.02 billion, an increase of 8.96% compared to the previous year's 933.81 million. Earnings were 429.43 million, an increase of 16.93%.

Financial Statements